{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T18:29:15Z","timestamp":1772821755975,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,14]]},"DOI":"10.7759\/cureus.38992","type":"journal-article","created":{"date-parts":[[2023,5,14]],"date-time":"2023-05-14T09:24:43Z","timestamp":1684056283000},"source":"Crossref","is-referenced-by-count":1,"title":["Atraumatic Splenic Rupture: A Notable Complication of Rivaroxaban Use"],"prefix":"10.7759","author":[{"given":"Catherine A","family":"Ostos Perez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Menchaca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Can X","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Ostos Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaun","family":"Isaac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/clc.23690","article-title":"Effects of rivaroxaban and warfarin on the risk of gastrointestinal bleeding and intracranial hemorrhage in patients with atrial fibrillation: Systematic review and meta-analysis","volume":"44","author":"Jiang H","year":"2021","unstructured":"Jiang H, Jiang Y, Ma H, Zeng H, Lv J. Effects of rivaroxaban and warfarin on the risk of gastrointestinal bleeding and intracranial hemorrhage in patients with atrial fibrillation: Systematic review and meta-analysis. Clin Cardiol. 2021, 44:1208-15. 10.1002\/clc.23690","journal-title":"Clin Cardiol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.21222","article-title":"Association of rivaroxaban vs apixaban with major ischemic or hemorrhagic events in patients with atrial fibrillation","volume":"326","author":"Ray WA","year":"2021","unstructured":"Ray WA, Chung CP, Stein CM, et al.. Association of rivaroxaban vs apixaban with major ischemic or hemorrhagic events in patients with atrial fibrillation. JAMA. 2021, 326:2395-404. 10.1001\/jama.2021.21222","journal-title":"JAMA"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly SJ","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, et al.. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009, 361:1139-51. 10.1056\/NEJMoa0905561","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-782060","article-title":"Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study","volume":"130","author":"Majeed A","year":"2017","unstructured":"Majeed A, \u00c5gren A, Holmstr\u00f6m M, et al.. Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study. Blood. 2017, 130:1706-12. 10.1182\/blood-2017-05-782060","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman S","year":"2005","unstructured":"Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005, 3:692-4. 10.1111\/j.1538-7836.2005.01204.x","journal-title":"J Thromb Haemost"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-563577","article-title":"Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry","volume":"124","author":"Beyer-Westendorf J","year":"2014","unstructured":"Beyer-Westendorf J, F\u00f6rster K, Pannach S, et al.. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood. 2014, 124:955-62. 10.1182\/blood-2014-03-563577","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.9738\/INTSURG-D-14-00143.1","article-title":"Characteristics of patients with spontaneous splenic rupture","volume":"99","author":"Kocael PC","year":"2014","unstructured":"Kocael PC, Simsek O, Bilgin IA, Tutar O, Saribeyoglu K, Pekmezci S, Goksoy E. Characteristics of patients with spontaneous splenic rupture. Int Surg. 2014, 99:714-8. 10.9738\/INTSURG-D-14-00143.1","journal-title":"Int Surg"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/2050313X19832490","article-title":"Atraumatic splenic rupture associated with apixaban","volume":"7","author":"Basnet S","year":"2019","unstructured":"Basnet S, Mohanty E, Mir I, Dhital R, Koirala A, Tachamo N. Atraumatic splenic rupture associated with apixaban. SAGE Open Med Case Rep. 2019, 7:2050313X19832490. 10.1177\/2050313X19832490","journal-title":"SAGE Open Med Case Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cireng.2020.02.006","article-title":"Spontaneous splenic rupture associated with apixaban","volume":"98","author":"L\u00f3pez MAJ","year":"2020","unstructured":"L\u00f3pez MAJ, de la PLR, Latorre FRA, Medina VAA, Ramia \u00c1JM. Spontaneous splenic rupture associated with apixaban. Cir Esp Engl Ed. 2020, 98:164-165. 10.1016\/j.cireng.2020.02.006","journal-title":"Cir Esp Engl Ed"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2014.01.049","article-title":"Spontaneus splenic rupture in a patient treated with rivaroxaban","volume":"32","author":"Gonzva J","year":"2014","unstructured":"Gonzva J, Patricelli R, Lignac D. Spontaneus splenic rupture in a patient treated with rivaroxaban. Am J Emerg Med. 2014, 32:950.e3. 10.1016\/j.ajem.2014.01.049","journal-title":"Am J Emerg Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.22541\/au.165691632.29809902\/v1","article-title":"Atraumatic splenic rupture in a patient treated with rivaroxaban: a case report and a narrative review","author":"Labaki ML","year":"2022","unstructured":"Labaki ML, Kock MD. Atraumatic splenic rupture in a patient treated with rivaroxaban: a case report and a narrative review. Preprints. 2022, 10.22541\/au.165691632.29809902\/v1","journal-title":"Preprints"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2017-223237","article-title":"Spontaneous splenic rupture due to rivaroxaban","volume":"2018","author":"Nagaraja V","year":"2018","unstructured":"Nagaraja V, Cranney G, Kushwaha V. Spontaneous splenic rupture due to rivaroxaban. BMJ Case Rep. 2018, 2018:10.1136\/bcr-2017-223237","journal-title":"BMJ Case Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.5455\/ijsm.spleenrupture","article-title":"Spontaneous splenic rupture secondary to rivaroxaban: Rare but raising","volume":"2","author":"Naseem Z","year":"2016","unstructured":"Naseem Z, Mustaev M, Strekozov B. Spontaneous splenic rupture secondary to rivaroxaban: Rare but raising. Int J Surg Med. 2016, 2:134. 10.5455\/ijsm.spleenrupture","journal-title":"Int J Surg Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijscr.2020.04.050","article-title":"Atraumatic splenic rupture in a patient treated with apixaban: A case report","volume":"71","author":"Yau HV","year":"2020","unstructured":"Yau HV, Pradhan S, Mou L. Atraumatic splenic rupture in a patient treated with apixaban: A case report. Int J Surg Case Rep. 2020, 71:270-3. 10.1016\/j.ijscr.2020.04.050","journal-title":"Int J Surg Case Rep"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.6737","article-title":"Systematic review of atraumatic splenic rupture","volume":"96","author":"Renzulli P","year":"2009","unstructured":"Renzulli P, Hostettler A, Schoepfer AM, Gloor B, Candinas D. Systematic review of atraumatic splenic rupture. Br J Surg. 2009, 96:1114-21. 10.1002\/bjs.6737","journal-title":"Br J Surg"},{"key":"ref16","article-title":"Spontaneous rupture of the normal spleen; a surgical enigma","volume":"106","author":"Orloff MJ","year":"1958","unstructured":"Orloff MJ, Peskin GW. Spontaneous rupture of the normal spleen; a surgical enigma. Int Abstr Surg. 1958, 106:1-11.","journal-title":"Int Abstr Surg"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-016-1012-6","article-title":"Spontaneous splenic rupture associated with apixaban: a case report","volume":"10","author":"Lowry LE","year":"2016","unstructured":"Lowry LE, Goldner JA. Spontaneous splenic rupture associated with apixaban: a case report. J Med Case Rep. 2016, 10:217. 10.1186\/s13256-016-1012-6","journal-title":"J Med Case Rep"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.009530","article-title":"Impact of modifiable bleeding risk factors on major bleeding in patients with atrial fibrillation anticoagulated with rivaroxaban","volume":"9","author":"Kirchhof P","year":"2020","unstructured":"Kirchhof P, Haas S, Amarenco P, et al.. Impact of modifiable bleeding risk factors on major bleeding in patients with atrial fibrillation anticoagulated with rivaroxaban. J Am Heart Assoc. 2020, 9:e009530. 10.1161\/JAHA.118.009530","journal-title":"J Am Heart Assoc"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12863","article-title":"Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a \"real-world\" observational study in the United States","volume":"70","author":"Lip GY","year":"2016","unstructured":"Lip GY, Pan X, Kamble S, et al.. Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a \"real-world\" observational study in the United States. Int J Clin Pract. 2016, 70:752-63. 10.1111\/ijcp.12863","journal-title":"Int J Clin Pract"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2016.1.620","article-title":"What to do after the bleed: resuming anticoagulation after major bleeding","volume":"2016","author":"Witt DM","year":"2016","unstructured":"Witt DM. What to do after the bleed: resuming anticoagulation after major bleeding. Hematology Am Soc Hematol Educ Program. 2016, 2016:620-4. 10.1182\/asheducation-2016.1.620","journal-title":"Hematology Am Soc Hematol Educ Program"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/122049-atraumatic-splenic-rupture-a-notable-complication-of-rivaroxaban-use","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:59:46Z","timestamp":1707508786000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/122049-atraumatic-splenic-rupture-a-notable-complication-of-rivaroxaban-use"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,14]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.38992","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5,14]]}}}